Lyra Therapeutics (LYRA) CFO 10b5-1 tax sale of 769 shares reported

Rhea-AI Filing Summary

Lyra Therapeutics, Inc. Chief Financial Officer Jason Cavalier reported a small, pre-arranged sale of 769 shares of common stock. The sale occurred on 01/06/2026 at a price of $3.364 per share under transaction code "S." According to the filing, the shares were sold to cover taxes triggered by the vesting of restricted stock units under a mandatory Rule 10b5-1 trading instruction adopted on January 1, 2025.

Following this tax-withholding sale, Cavalier beneficially owns 518,547 shares of Lyra Therapeutics common stock in direct form. The transaction is characterized as administrative in nature, tied to equity award vesting rather than an open-market discretionary sale.

Insider Trade Summary

Net Seller: 769 shares ($2,587)

Net Sell 1 txn

Insider Cavalier Jason

Role Chief Financial Officer

Sold 769 shs ($3K)

Type	Security	Shares	Price	Value
Sale	Common Stock	769	$3.364	$3K

Holdings After Transaction: Common Stock — 518,547 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cavalier Jason

(Last) (First) (Middle)

C/O LYRA THERAPEUTICS, INC.

480 ARSENAL WAY

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lyra Therapeutics, Inc. [ LYRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		S(1)		769	D	$3.364	518,547	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were sold to cover taxes upon the vesting of restricted stock units ("RSUs") pursuant to a mandatory Rule 10b5-1 trading instruction in the award agreement adopted by the Reporting Person on January 1, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

	/s/ Jason Cavalier	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Lyra Therapeutics (LYRA) disclose in this Form 4?

The filing reports that Chief Financial Officer Jason Cavalier sold 769 shares of Lyra Therapeutics common stock on 01/06/2026 at a price of $3.364 per share.

Why did Lyra Therapeutics CFO Jason Cavalier sell 769 shares?

The filing states that the shares were sold to cover taxes upon the vesting of restricted stock units (RSUs) under a mandatory Rule 10b5-1 trading instruction in his award agreement.

How many Lyra Therapeutics (LYRA) shares does the CFO own after this transaction?

After the reported sale, Jason Cavalier beneficially owns 518,547 shares of Lyra Therapeutics common stock in direct ownership form.

Was the Lyra Therapeutics CFO’s sale a discretionary open-market trade?

No. The explanation states the sale was made under a mandatory Rule 10b5-1 trading instruction tied to RSU vesting, indicating it was pre-arranged in the award agreement rather than a discretionary trade.

What is the role of Jason Cavalier at Lyra Therapeutics (LYRA)?

Jason Cavalier is identified in the filing as an officer of Lyra Therapeutics, serving as Chief Financial Officer and is not listed as a director or 10% owner.

Does this Form 4 report any Lyra Therapeutics derivative securities transactions?

No derivative securities entries are shown in Table II; the filing only reports a non-derivative common stock transaction related to tax withholding on RSU vesting.